Josephine Vaglio, - Hillside Public Library

DRHEA Masterclass in
Translational Cancer
Research
A two day course outlining the principles and practice of modern
multidisciplinary translational cancer research.
Venue: NICB Seminar Room, Dublin City University
Date: Friday 4th & 11th April 2014
Attendance: you must register through http://goo.gl/U2rcR5 or
https://www.eventbrite.com/e/masterclass-in-translational-cancerresearch-2-day-course-442014-1142014-tickets-11073815079
or
contact [email protected] for further details
Attendance is limited and on “a first come first served basis” to those
engaged in cancer research. The registration charge for nonDRHEA/ non-ICORG attendees is €350
For students from DRHEA-linked colleges, this course has credit rating of 2.5.
Cancer research is making rapid advances through
interdisciplinary collaborations between science, medicine
and industry.
Led by leading researchers from translational cancer
research disciplines, this class will give students, scientists,
clinicians, nurses and pharma industry representatives an
understanding of practice, perspectives and pitfalls in a
modern translational cancer research effort.
Masterclass in Translational Cancer
Research
April 4th and 11th 2014, NICB Seminar room,
Dublin City University
Draft Course Schedule
Friday April 4th
Date
Time
9.00-9.15
9.15-9.30
Title
Registration
Welcome and
Introduction
Concept
Speaker
Welcome and introduction
9.30-10.15
Introduction to
Translational Cancer
Research
Background and challenges in
Translational Cancer Research
Prof. Martin Clynes,
Director – National Institute for
Cellular Biotechnology, DCU
Dr. Robert O’Connor
Senior Programme Leader in
Translational Cancer
Pharmacology, NICB, DCU.
Chair, Translational group, ICORG,
10.15 -10.30
10.30-11.15
Coffee break
ICORG – Ireland’s
National Clinical
Cancer Research
Network
Ethics committees
Operations and research role of
ICORG
Dr. Fionnuala Keane, Clinical
Project Manager, ICORG
Translational research
considerations from the
perspective of the ECs
Translational and early stage
clinical trial research from the
perspective of a hospital
pharmacist
David Willow, SJH/Tallaght REC
11.15-12.00
12.00-12.45
12.45-1.30
1.30-2.15
Pharmacy and
Pharmaceutical
Considerations in
Translational Research
Lunch break
The industry
perspective on cancer
drug development &
translational research
2.15-3.00
Clinical Research in
Cancer
3-3.15
3.15-4.00
Coffee break
Diagnosis Prognosis
and Staging of cancer
4.00-4.45
Mutation Analysis in
Translational research
How Biomarkers Help
Patients with Cancer
4.45 – 5.30
Ruth McHugh, Chief II Research
Pharmacist, Wellcome trust – HRB
Clinical Research Facility, St.
James’s Hospital
The research realities for cancer Dr. Grainne Power, Head of
drug development from an Irish Clinical Operations, RD Projects
Pharma Affiliate perspective
Clinical Platforms & Sciences –
Ireland,
GSK Ireland
Perspectives on how cancer is
Senator, Prof. John Crown,
treated and researched
Medical Oncologist, SVUH;
Director –MTCI/NCRCI
How cancer is diagnosed and
staged and what material is
available for research
How to identify mutation in
cancer tissue
Development and discussion of
practicalities cancer biomarkers
Dr. Ann Treacy, Consultant
Pathologist,
Dr. Sinead Toomey, Researcher,
Dept of Medical Oncology, RCSI
Prof. Joe Duffy, St Vincent's
University Hospital and University
College, Dublin
Friday April 11th
Date
Time
9.00 -10.15
10.15-10.30
10.15- 11.00
11.00- 11.45
11.45-12.30
12.45 – 1.30
2-2.45
2.45-3.30
3.00-3.15
3.15–4.00
4.00 -4.45
4.45-5
Title
Summary of emerging
tools & resources
relevant to cancer
drug development
Coffee Break
Translational Clinical
trial design
Translational Protocol
development
Antibodies in
translational cancer
research
Lunch break
Practical issues at the
patient Interface
Data management in
clinical studies
Coffee Break
Transcriptomic
methods in cancer
research
Proteomic methods in
cancer research
MCQ –based
assessment
Concept
The modern cancer drug
development process
Speaker
Dr. Robert O’Connor
A clinician’s perspective on the
rationale and design of
translational clinical trials
Basic issues developing
translational protocols
Applications and use of
antibodies in cancer research
Dr. Ray McDermott, Medical
Oncologist, AMNCH and SVUH,
ICORG clinical leader
Dr. Verena Murphy, Translational
Research Manager, ICORG & MTCI
Dr. AnneMarie Larkin, Senior
Research Scientist - Monoclonal
Antibody Research Programme,
NICB
Translational research from the
research nurse perspective
Perspectives on generating
handling and managing high
quality study data
Ms. Jo Ballot, Research Nurse
Manager, CCRT, SVUH
Peter Haughton, Data manager,
CCRT, St. Vincent’s University
Hospital
Applications and procedures in
translational cancer
transcriptomics
Applications and procedures in
translational cancer proteomics
Dr. Sinead Aherne, Transcriptional
Researcher, NICB
Compulsory examination for
those looking for DRHEA course
credit
Dr. Paul Dowling, Programme
Leader in Clinical Proteomics,
NICB
Robert O’Connor
5 close
Contact Dr. Robert O’Connor on [email protected] for further details on this masterclass.
Spaces can be booked using the following website http://goo.gl/U2rcR5
The masterclass will take place in the seminar room of the NICB at Dublin City University, see attached map
for directions.
`